BC
DGX icon

Bayforest Capital’s Quest Diagnostics DGX Stock Holding History

Bayforest Capital’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$35.8K Buy
+169
New +$33.2K 0.03% 704
2025
Q4 		– Sell
-1,619
Closed -$309K – 832
2025
Q3 		$309K Buy
+1,619
New +$287K 0.15% 283

Other funds holding DGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Bayforest Capital's DGX Position: Q2 2026 in Review

Bayforest Capital opened a new position in Quest Diagnostics (DGX) in Q2 2026: 169 shares worth $35.8K. The stake represents 0.03% of the portfolio and ranks #704 among its holdings. This is a return to the name: Bayforest Capital previously reported a position in DGX as recently as Q3 2025.

Bayforest Capital first reported a position in DGX in Q3 2025 and has held it in 2 quarters since. The position peaked at $309K in Q3 2025. 1,105 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

  • Bayforest Capital held 169 shares of Quest Diagnostics worth $35.8K as of Q2 2026.
  • Quest Diagnostics was a new Bayforest Capital position in Q2 2026.
  • Quest Diagnostics made up 0.03% of Bayforest Capital's portfolio in Q2 2026, its #704 holding.
  • Bayforest Capital first reported a position in Quest Diagnostics in Q3 2025 and has held it in 2 quarters since.
  • Bayforest Capital's Quest Diagnostics position peaked at $309K in Q3 2025.
  • 1,105 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Bayforest Capital's 13F filing for Q2 2026, filed 5 Aug 2026.